BLOG
FDA – OA REMS Announcement Concerning requirements to Manufacturers of Opioids
New FDA - OA REMS Announcement | by: Deneen Fumich, RPh | Article Posted: May 2, 2023 | April 21, 2022, FDA published in the Federal Register open comments under the Support Act which authorized FDA to require through a Risk Evaluation and Mitigation Strategy (REMS)...
Recent Articles
The Increasing Trend of Drug Price Transparency
The Increasing Trend of Drug Price Transparency There are presently nineteen states with drug price transparency laws, and an additional ten more...
Top 5 Mistakes Pharmacies Make During URAC Accreditation
Top 5 Mistakes Pharmacies Make During URAC Accreditation navigating clients through URAC accreditation, I've found the most problematic areas for...
MDMA in Phase 3 Trials for FDA Approval
MDMA in Phase 3 Trials for FDA Approval Phase 3 trials are already underway for MDMA as treatment for PTSD. The effort is spearheaded by MAPS, who...
NABP Accused of Enforcing ‘Shadow Regulation’ Twice in 3 years
NABP Accused of Enforcing ‘Shadow Regulation’ Twice in 3 years NABP is a private organization that mostly earns revenue by offering various services...
CalRecycle Safety Regulations
CalRecycle Safety Regulations The Pharmaceutical and Sharps Waste Stewardship Act Regulations were adopted on January 7, 2021 (Public Resources...
Oregon Passes Pharmaceutical Representative Licensure & Disclosure Law
Oregon Passes Pharmaceutical Representative Licensure & Disclosure Law, Effective January 1, 2022 On July 19, 2021, Oregon’s Governor, Kate...
